Zhifei Biological's meningococcal vaccine application accepted

Chongqing Zhifei Biological Products (SZSE:300122) announced that its wholly-owned subsidiary, Beijing Zhifei Green Bamboo Pharmaceutical, has received notification from the National Medical Products Administration (NMPA) that its application for production registration of the ACYW135 quadrivalent meningococcal conjugate vaccine has been accepted. The vaccine is designed to prevent meningitis caused by A, C, Y, and W135 serogroups of Neisseria meningitidis. If approved and launched, it will synergize with Zhifei's existing meningitis vaccines, strengthening its market position. While this acceptance does not have a significant impact on the company’s near-term financial performance, it could positively influence future operations. The company cautioned that the vaccine is still subject to technical review and other regulatory processes, and that there is no guarantee it will be approved.